obesity/seizures

CROSS REFERENCE TO RELATED APPLICATIONS This application is a National Stage of International Application No. PCT/JP2012/081744 filed Dec. 7, 2012, claiming priority based on Japanese Patent Application No. 2011-268561 filed Dec. 8, 2011, the contents of all of which are incorporated herein by

TECHNICAL FIELD The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual

TECHNICAL FIELD The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual

TECHNICAL FIELD The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual

Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic

Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic

Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic

TECHNICAL FIELD The present invention is useful in medical fields. In more detail, novel imidazoline compounds of this invention are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of cardiovascular disorders, central nervous system disorders, metabolic

This application is a 371 of PCT/JP01/01312 filed Feb. 22, 2001. TECHNICAL FIELD The present invention is useful in medical fields. In more detail, novel imidazoline compounds of this invention are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of

FIELD OF THE INVENTION This invention relates generally to the field of non-human, transgenic animal models and more particularly to a transgenic mouse model useful in the testing of drugs for their efficacy in the treatment of eating disorders and epilepsy. BACKGROUND OF THE INVENTION Serotonin,

This application is a U.S. national stage of International Application No. PCT/JP03/03115 filed Mar. 14, 2003. TECHNICAL FIELD The present invention is useful in medical fields. In more detail, novel pyridone derivatives of the present invention have an effect as neuropeptide Y receptor antagonists

This application is a U.S. national stage of International Application No. PCT/JP02/07922 filed Aug. 2, 2002. TECHNICAL FIELD The present invention is useful in medical fields. In more detail, spiro compounds of the present invention have an effect as neuropeptide Y receptor antagonists and are

CROSS REFERENCE TO RELATED APPLICATIONS This is a National Stage of International Application No. PCT/JP2009/067441 filed Sep. 30, 2009, claiming priority based on Japanese Patent Application No. 2008-257072 filed Oct. 2, 2008, the contents of all of which are incorporated herein by reference in

FIELD OF THE INVENTION The present invention generally relates to deuterium-enriched N-acetylamino-(piperazinyl)-butyl)-alkylsulfonamides of formula 1, their pharmaceutically acceptable salts, synthesis and methods of use thereof. These compounds are 5-HT (serotonin) receptor modulators more

CROSS REFERENCE TO RELATED APPLICATION This application claims the priority of Korean Patent Application No. 10-2007-0022845, filed on Mar. 8, 2007 in the KIPO (Korean Intellectual Property Office), the disclosure of which are incorporated herein in their entirety by reference. Further, this